Mirum Pharmaceuticals (NASDAQ:MIRM – Get Free Report) and Kiniksa Pharmaceuticals International (NASDAQ:KNSA – Get Free Report) are both mid-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, dividends, valuation, profitability, institutional ownership, risk and analyst recommendations.
Valuation & Earnings
This table compares Mirum Pharmaceuticals and Kiniksa Pharmaceuticals International”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Mirum Pharmaceuticals | $521.31 million | 10.46 | -$23.36 million | ($14.55) | -5.77 |
| Kiniksa Pharmaceuticals International | $677.56 million | 9.13 | $59.01 million | $0.97 | 81.76 |
Profitability
This table compares Mirum Pharmaceuticals and Kiniksa Pharmaceuticals International’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Mirum Pharmaceuticals | -139.18% | -36.28% | -8.54% |
| Kiniksa Pharmaceuticals International | 9.59% | 13.65% | 10.09% |
Risk & Volatility
Mirum Pharmaceuticals has a beta of 0.61, indicating that its stock price is 39% less volatile than the S&P 500. Comparatively, Kiniksa Pharmaceuticals International has a beta of 0.04, indicating that its stock price is 96% less volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of current ratings and target prices for Mirum Pharmaceuticals and Kiniksa Pharmaceuticals International, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Mirum Pharmaceuticals | 1 | 0 | 13 | 1 | 2.93 |
| Kiniksa Pharmaceuticals International | 0 | 1 | 8 | 0 | 2.89 |
Mirum Pharmaceuticals currently has a consensus target price of $146.12, indicating a potential upside of 74.01%. Kiniksa Pharmaceuticals International has a consensus target price of $93.14, indicating a potential upside of 17.45%. Given Mirum Pharmaceuticals’ stronger consensus rating and higher probable upside, research analysts plainly believe Mirum Pharmaceuticals is more favorable than Kiniksa Pharmaceuticals International.
Institutional & Insider Ownership
53.9% of Kiniksa Pharmaceuticals International shares are owned by institutional investors. 8.3% of Mirum Pharmaceuticals shares are owned by company insiders. Comparatively, 52.0% of Kiniksa Pharmaceuticals International shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Summary
Kiniksa Pharmaceuticals International beats Mirum Pharmaceuticals on 9 of the 15 factors compared between the two stocks.
About Mirum Pharmaceuticals
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.
About Kiniksa Pharmaceuticals International
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.
Receive News & Ratings for Mirum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
